Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better healthREQUIREMENTS FOR PRODUCT APPROVALThe pharmaceutical industry, including BoehringerIngelheim, is facing increasing difficulties to achievemarket access, i.e. reimbursement for the labelledportfolio of new innovative products.budgetimpactTHREE TRADITIONAL REQUIREMENTSProvision of evidence to demonstratesafety, efficacy and quality for purposes ofregistration and reimbursement of newmedications.value and costeffectivenessFOURTH REQUIREMENT:VALUE AND COST-EFFECTIVENESSqualityefficacysafetythree traditional requirementsfourthrequirementfifthrequirementHealthcare providers’ expenses for treatmentsare covered or reimbursed by a payer.This payer must be convinced of theadditional clinical, as well as the economicbenefit of the product to be willing to payfor it.fied a difference in stakeholders’ andcustomers’ value perception of externalmarket access compared with our convictionabout the innovation and medicalneed of the two products.Unlike in previous years, we also noteda mismatch between rather positivehealth technology assessment (HTA)outcomes and the finally implementedreimbursement and pricing decisions –most likely driven by payers’ increasinghealthcare budget constraints. As a result,physicians and patients often hadto wait longer than expected to get accessto pradaxa® or trajenta®.Market access embeddedTherefore, our market access group isan integrated part of committees inR&D, Marketing and Regulatory toalign evaluations and decisions with asufficient focus on market access in thepreparation of research and developmentmilestone decisions.Progressive market access modelsFaced with fast-changing healthcaresystems, we have started to explore anddevelop non-traditional market accessmodels, such as risk-sharing agreementsand outcome/performance-based agreementswith some payers. Tiered pricing,i.e. pricing in accordance with the abilityof societies to generate income percapita, might be a way to bring newmedicines to a wider group of eligiblepatients in emerging markets.Every market is different and we needto clearly understand each payer’sneeds and ability to finance new medicines,whether the payer is a third party(i.e. health insurer) or the actual patient.Budget constraints are expectedto continue in many markets and eachmarket needs a different solution.Demonstrating the overall benefit of a newproduct, i.e. in the form of so-called costbenefitmodels, has to be cleared by theresearch-driven pharmaceutical industry.Payers are assessing the benefits of anynew medicine before granting access tothe respective healthcare systems.FIFTH REQUIREMENT:BUDGET IMPACTAddressing the budget impact is the ultimatechallenge for gaining market accessat national, regional and local levels.Market access for new medicines85